Won Gyu-jang
Yeungnam University Hospital|Endocrinology and Metabolism
Daegu Nam-gu
Last updated
Professor Won Gyu-jang's expertise is demonstrated by clinical work and academic achievements specializing in diabetes and endocrine and metabolic diseases.
Medical opinions · Patient reviews0
No reviews yet.
If you've been treated by Won Gyu-jang, be the first to leave a review.
Planning to see Won Gyu-jang?
Save this doctor and find them again anytime on My page.
Ask other patients
If reviews don't answer your questions, ask patients and caregivers who have been there.
Patient stories: Endocrinology and Metabolism
MoreHospital information
- Hospitals
- Yeungnam University Hospital
- Specialties
- More Endocrinology and Metabolism doctors
- Address
- 170 Hyeonchung-ro, Nam-gu, Daegu
- University
- 영남대학교 의과대학
- Appointments
- 053-620-4030Book by phone (053-620-4030)
Education and career
Education
- Graduated from Yeungnam University College of Medicine
- Doctor of Medicine
Career
- Training at Pacific Northwest Research Institute, Seattle
- Current: Director of Biomedical Research, Yeungnam University Medical Center
- Director, Innovative Physician-Scientist Joint Research Project, Yeungnam University Hospital
- Director of Planning and Coordination, Yeungnam University Medical Center
- Secretary-General
- Director of QI
- Vice Dean for Academic Affairs, Yeungnam University College of Medicine
- Chief of Internal Medicine, Yeungnam University Hospital
- Director of the Health Promotion Center
Academic societies
- 《Published Papers》
- 2023 Moon JS, Kim NH, Na JO, Cho JH, Jeong IK, Lee SH, Mok JO, Kim NH, Chung DJ, Cho J, Lee DW, Lee SW, Won KC. Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance. Diabetes b J. 2023 Jan;47(1):82-91. doi: 10.4093/dmj.2021.0356. Epub 2022 Jun 20
- 2022 Chung SM, Heo DG, Kim JH, Yoon JS, Lee HW, Kim JY, Moon JS, Won KC. compounds in adults and their association with fasting glucose and incident diabetes: a prospective cohort study. Environ Health. 2022 Oct 26;21(1):101. doi: 10.1186/s12940-022-00915-2
- 2022 Karunakaran U, Elumalai S, Moon JS, Won KC. c-Abl Tyrosine Kinase Inhibition Attenuate Oxidative Stress-Induced Pancreatic β-Cell Dysfunction via Glutathione Antioxidant System. Transl Res 2022 Jun 10;S1931-5244(22)00139-6. doi: 10.1016/j.trsl.2022.06.007
- 2022 Park IR, Choi J, Ha EY, Chung SM, Moon JS, Shin S, Kim SG, Won KC. Critical shear stress of red blood cells as a novel integrated biomarker for screening chronic kidney diseases in cases of type 2 diabetes. Clin Hemorheol Microcirc. 2022;81(4):293-303. doi: 10.3233/CH-211326.
- 2021 Elumalai S, Karunakaran U, Moon JS, Won KC. Pioglitazone-Induced AMPK-Glutaminase-1 Prevents High Glucose-Induced Pancreatic β-cell Dysfunction by Glutathione antioxidant system. Redox Biol. https://doi.org/10.1016/j.redox.2021.102029
- 2020 Elumalai S, Karunakaran U, Moon JS, Won KC. High glucose-induced PRDX3 acetylation contributes to glucotoxicity in pancreatic β-cells: Prevention by teneligliptin. Free Radic Biol Med 2020, 618-629.
- 2019 Moon JS, Chung SM, Jang SH, Won KC*, Chang MC. (co-correspondence) Effects of Diabetes on Motor Recovery after Cerebral Infarct: A Diffusion Tensor Imaging Study. J Clin Endocrinol b. 2019 Apr 4. pii: jc.2018-02502. (Epub ahead of print).
- 2019 Karunakaran U, Elumalai S, Moon JS, Jeon JH, Kim ND, Park KG, Won KC, Leem J, Lee IK. Myricetin Protects Against High Glucose-Induced β-Cell Apoptosis by Attenuating Endoplasmic Reticulum Stress via Inactivation of Cyclin-Dependent Kinase 5. Diabetes b J. 2019 Jan 16. [Epub ahead of print]
- 2019 Karunakaran U, Elumalai S, Moon JS, Won KC* (*co-corresponding). CD36 dependent redoxosomes promotes ceramide-mediated pancreatic β-cell failure via p66Shc activation. Free Radic Biol Med. 2019;134:505-515.
- 2019 Chung SM, Moon JS, Yoon JS, Won KC*, Lee HW. Sex-specific effects of blood cadmium on thyroid hormones and thyroid function status: Korean nationwide cross-sectional study. J Trace Elem Med Biol. 2019; 53:55-61
- 2018 Won KC. A Short but Long Journey with You.DIABETES & BOLISM JOURNAL. 42(1)
- 2018 Won KC et al. Smart Care d on Telemonitoring and Telemedicine for Type 2 Diabetes Care: Multi-Center Randomized Controlled Trial. TELEMEDICINE AND E-HEALTH. 24(8)
- 2018 Won KC et.al.Low urine pH affects the development of bolic syndrome, associative with the increase of dyslipidemia and dysglycemia: Nationwide cross-sectional study (KNHANES 2013-2015) and a single-center retrospective cohort study. PLOS ONE. 13(8) e0202757 (*co-correspondence)
- 2017 Elumalai S, Karunakaran U, Lee IK, Moon JS, Won KC. Rac1-NADPH oxidase signaling promotes CD36 activation under glucotoxic conditions in pancreatic beta cells. Redox Biol. 11: 126–134 (*co-correspondence)
- 2017 Moon JS, Karunakaran U, Elumalai S, Lee IK, Lee HW, Kim YW, Won KC. Metformin prevents glucotoxicity by alleviating oxidative and ER stress-induced CD36 in pancreatic beta cells. J Diabetes Complications. 31:21-30 (Correspondance)
- 2016 Moon JS, Kim JH, Kim JH, Park IR, Lee JH, Kim HJ, Lee J, Kim YK, Yoon JS, Won KC*, Lee HW. Impaired RBC deformability is associated with diabetic retinopathy in patients with type 2 diabetes. Diabetes b. 42:448-452, (*co-correspondence)
- 2016 Yoon JS, Moon JS, Kim YW, Won KC, Lee HW. The Glucotoxicity Protecting Effect of Ezetimibe in Pancreatic Beta Cells via Inhibition of CD36. J Korean Med Sci. 2016 Apr; 31(4):547-552 (Correspondance)
- 2015 Karunakaran U, Moon JS, Lee HW, Won KC. CD36 initiated signaling mediates ceramide-induced TXNIP in pancreatic beta-cells. Biochim Biophys Acta. 2015 ;1852(11):2414-22 (Correspondance)
- 2015 Moon JS, Won KC. Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block. Diabetes b J. 2015;39(1):1-9
- 2014 Moon JS, Ha KS, Yoon JS, Lee HW, Lee HC, Won KC; BETA study group. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study. Acta Diabetol. 2014;51(2):277-85
- 2013 Moon JS, Yoon JS, Won KC, Lee HW. The role of skeletal muscle in development of nonalcoholic Fatty liver disease. Diabetes b J. 2013;37(4):278-85
- 2013 Chung HH, Moon JS, Yoon JS, Lee HW, Won KC. The Relationship between Metformin and Cancer in Patients with Type 2 Diabetes. Diabetes b J. 2013 Apr;37(2):125-31
- 2012 Kim YW, Moon JS, Seo YJ, Park SY, Kim JY, Yoon JS, Lee IK, Lee HW, Won KC. Inhibition of fatty acid translocase cluster determinant 36 (CD36), stimulated by hyperglycemia, prevents glucotoxicity in INS-1 cells. Biochem Biophys Res Commun. 2012 ;420(2):462-6
- Chairman of the Korean Diabetes Association (2022–2023)
- Former: Vice President of the Korean Endocrine Society
- Director of Research, Korean Endocrine Society
- Director of Publications and Director of Academic Affairs, Korean Diabetes Association
- President of the Daegu-Gyeongbuk Endocrine and Diabetes Society Branch
- Council Member, Korean Diabetes Association
- Council Member, Korean Endocrine Society
- Council Member, Korean Association of Internal Medicine
- Full Member, American Diabetes Association
- Full Member, Endocrine Society
FAQ
- Where does Won Gyu-jang see patients?
- In Endocrinology and Metabolism at Yeungnam University Hospital. The hospital address is 170 Hyeonchung-ro, Nam-gu, Daegu.
- What is Won Gyu-jang's specialty?
- Specialty: Endocrinology and Metabolism.
Is any information wrong?
Let us know about changes to hospital, specialty, career and so on, and we'll update it after checking.